US, Europe, and Brazil Alopecia Market Size, Share, Growth Analysis, By Treatment(Surgical [Hair Transplant {Follicular Unit Transplantation (FUT), and Follicular Unit Extraction (FUE)}, Alopecia Scalp Reduction, Scalp Expansion), By Region - Industry Forecast 2024-2031

Due to rising knowledge of alopecia treatments and increased acceptance of alopecia treatment products, Asia-Pacific offers lucrative prospects for key players operating in the alopecia treatment market. Additionally, the expansion of hospitals with cutting-edge medical facilities, and improvement in healthcare infrastructure, progress in the R&D sector, an increase in healthcare reforms, and technical developments in the healthcare industry all contribute to the market's expansion.

Top Player’s Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)

• Mylan N.V. (US)

• Teva Pharmaceutical Industries Ltd. (Ireland)

• Sanofi (France)

• Pfizer Inc. (US)

• GlaxoSmithKline plc (UK)

• Novartis AG (Switzerland)

• Bayer AG (Germany)

• Eli Lilly and Company (US)

• Merck & Co., Inc. (US)

• Allergan (Ireland)

• AstraZeneca (UK)

• AbbVie Inc. (US)

• Johnson & Johnson Private Limited (US)

• Cipla Inc. (US)  

• Abbott Pharmacy (US)

• BioNike (Italy)

• Daichii Sanko (Japan)

• Theradome (US)

• Lutronic Corporation (US)

Recent Development

• In June 2023, Pfizer Inc. disclosed that the U.S. Food and Drug Administration (FDA) has granted approval for LITFULO (ritlecitinib), an oral treatment taken once daily, for individuals aged 12 and above with severe alopecia areata. The FDA's approval recommends a dosage of 50 mg for LITFULO. Notably, LITFULO is the first and sole treatment sanctioned by the FDA for adolescents aged 12 and older grappling with severe alopecia areata.

• In June 2022, Eli Lilly and Company and Incyte jointly announced that the U.S. Food and Drug Administration (FDA) has granted approval for OLUMIANT (baricitinib), a once-daily pill, as the first systemic treatment for adults with severe alopecia areata (AA). OLUMIANT is available in 4-mg, 2-mg, and 1-mg tablets, with the recommended dosage being OLUMIANT 2-mg/day initially. If the treatment response is inadequate, the dosage may be increased to 4-mg/day. For patients experiencing nearly complete or total scalp hair loss, with or without significant eyelash or eyebrow hair loss, treatment with 4-mg/day is advised. Upon achieving an adequate response with 4-mg/day, the dosage should be reduced to 2-mg/day. It's important to note that OLUMIANT is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.